Top Markets
#1 Black Phoenix Black Phoenix +355.39%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +62.70%
#4 Akedo Akedo +56.63%
#5 OpenEden OpenEden +54.44%
#6 BasedHype BasedHype +27.45%
#7 Avantis Avantis +21.78%
#8 Cryptopia Cryptopia +21.54%
#9 Acurast Acurast +19.36%
#10 Humanity Humanity +17.48%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Classifica tra le azioni #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Prezzo delle azioni
$0.01292666
Ultima sincronizzazione: 2025-04-08
Capitalizzazione di mercato
$157.54K
Variazione (1 giorno)
6.84%
Variazione (1 anno)
0.00%
Paese
GB
Scambia Synairgen plc (SNG)

Categoria

Healthcare
Rapporto P/B per Synairgen plc (SNG)
Rapporto P/B al August 2026 TTM: 0.15
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Synairgen plc, il rapporto P/B attuale (TTM) è 0.15. Alla fine del 2022, era pari a 0.97.
Storico del rapporto P/B per Synairgen plc da 2004 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 0.15 -78.10%
2023 0.69 -29.11%
2022 0.97 -88.10%
2021 8.13 326.23%
2020 1.91 -7.27%
2019 2.06 -99.86%
2018 1.50K 26.76%
2017 1.18K -39.85%
2016 1.97K -1.83%
2015 2.01K -7.72%
2014 2.17K 11,509.79%
2013 18.72 170.50%
2012 6.92 224.88%
2011 2.13 16.99%
2010 1.82 206.96%
2009 0.59 -73.97%
2008 2.28 35.55%
2007 1.68 -99.48%
2006 322.75 18.54%
2005 272.28 1,051.93%
2004 23.64 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 4,043.81%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 4,101.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 2,305.03%
BE